Published in AIDS Weekly, April 24th, 2006
In a recently published article, scientists in the United States conducted an open-label, randomized, multiple dose, two-period crossover study to compare the "pharmacokinetics, safety/tolerability and antiviral activity" of once-daily 180 mg enfuvirtide versus twice daily 90 mg enfuvirtide.
"Steady-state intensive pharmacokinetic samples were obtained on days 7 and 14. Thirty-seven subjects received at least one dose of enfuvirtide. Thirty-three subjects completed both dosing periods," researchers said.
According to M....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.